




UNITED STATES PATENT AND TRADEMARK OFFICE




**COPY**

2516-US

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
✓ 10/552,327	Ee Chee Ren	✓ 22516-US

22829  
ROCHE MOLECULAR SYSTEMS INC.  
PATENT LAW DEPARTMENT  
1145 ATLANTIC AVENUE  
ALAMEDA, CA 94501



INTERNATIONAL APPLICATION NO.	
PCT/SG04/00103	

I.A. FILING DATE	PRIORITY DATE
04/21/2004	04/21/2003

**CONFIRMATION NO. 8907**  
**371 FORMALITIES LETTER**



\*OC000000019636914\*

Date Mailed: 07/17/2006

## **NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

**For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:**

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

CHARITTA A BURT

Telephone: (703) 308-9140 EXT 207

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/552,327	PCT/SG04/00103	22516-US

FORM PCT/DO/EO/922 (371 Formalities Notice)

COPY

ROCHE MOLECULAR SYSTEMS

File No.	22516-US 5
Date/By	7-26-06
Attorney	SAP / HIL
Action	Seq. Listings
Due Date	9/17/06
Final Date	1/17/07

CERTIFICATE OF MAILING (37 CFR 1.8a)



I hereby certify that this paper (along with any paper referred to as being transmitted therewith) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

Date: 8-1-06

By:   
Winsome St. Rose

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**IN RE APPLICATION OF:**

EE Chen Ren, et al.

SERIAL NO.: 10/552,327

INTERNATIONAL FILING DATE: APRIL 21, 2004

FOR: REAGENTS AND METHODS FOR  
DETECTING SEVERE ACUTE  
RESPIRATORY SYNDROME  
CORONAVIRUS

)

) EXAMINER: N/A

) ART UNIT: N/A

) Confirmation No. N/A

) DOCKET NO 22516-US5

**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE AND /OR AMINO ACID SEQUENCES  
DISCLOSURES**

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

In response to the Notification to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures of Application mailed July 17, 2006, applicants hereby submit the following:

- Copy of the Notification to Comply mailed July 17, 2006.
- Statement Under 37 C.F.R. §1.821, and
- CRF and Paper copies of the Sequence Listings.

Respectfully submitted,

Date: August 1, 2006

  
Christopher C. Sappenfield  
Reg. No. 45,073

ROCHE MOLECULAR SYSTEMS, INC.  
1145 Atlantic Avenue  
Alameda, CA 94501  
Tele: 510-814-2800  
Fax: 510-814-2973  
Customer No. 22829